Lerapolturev NCT06177964 Clinical Landscape 2026

Explore the PatSnap Life Sciences MCP marketplace

This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.

Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.

Phase 2

Clinical phase

Recruiting

Recruitment status

not reported

Planned enrollment

2029-02-01

Primary-completion proxy

Executive view

NCT06177964 evaluates Lerapolturev in Glioblastoma Multiforme. The disclosed sponsor is Duke University, the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Proportion of patients at each dose level who experienced a dose-limiting toxicity - Stage 1, assessed over Up to 1 year.

The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.

PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.

How the MCP evidence stack was assembled

Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT06177964 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Glioblastoma Multiforme landscape. Drug & Asset MCP drug_fetch was queried for Lerapolturev, while Company & Deal Intelligence MCP organization_fetch was queried for Duke University.

This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.

Trial landscape table

Trial	Asset / intervention	Phase / status	Sponsor	Geography	Primary endpoint	Readout proxy
NCT06177964	Lerapolturev	Phase 2 / Recruiting	Duke University	United States	Proportion of patients at each dose level who experienced a dose-limiting toxicity - Stage 1 Up to 1 year	2029-02-01
NCT06703255	Temozolomide	Phase 1/2 / Recruiting	Hangzhou Hansi Biological Pharmaceutical Co., Ltd.	China	Part I: Number of participants experiencing Adverse Events (AEs) All AEs up to 28(±7)days after the last dose of study treatment	2026-12-31
NCT06691308	WL-276 (Imunopharm)	Early Phase 1 / Not yet recruiting	Beijing Imunopharm Technology Co., Ltd.	Geography not reported	Evaluate the safety（Adverse event incidence rate、Incidence rate of abnormal laboratory test results） and tolerability（D… Within 28 days after infusion	2027-05-31
NCT06687681	Allogenic NK cell(Kian Immune Cell Company)	Phase 2 / Recruiting	Kian immune Cell Company	Iran	To measure tumor response after infusion of intrathecal NK cells From enrollment to the end of treatment at 12 months	2025-11-25
NCT06672575	Ivonescimab	Phase 1/2 / Recruiting	The University of Texas MD Anderson Cancer Center	United States	Safety and Adverse Events (AEs) Through study completion; an average of 1 year	2028-01-31

The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.

Reproduce the trial-to-asset workflow with PatSnap MCP

Protocol design and endpoint interpretation

NCT06177964 is a Phase 2, recruiting study with not reported planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.

The primary endpoint is “Proportion of patients at each dose level who experienced a dose-limiting toxicity - Stage 1” over “Up to 1 year.” The retrieved endpoint description is: Dose-limiting toxicities (DLTs) are defined as any of the following events that are possibly, probably, or definitely attributable to study treatment (i.e., lerapolturev) during dose escalation (Stage 1): * Any Grade 3 or any Grade 4 toxicity within 2 weeks, including cerebral edema or worsening neurologic symptoms * Any life-threatening event within 2 weeks * Treatment-related death at least possibly, probably, or definitely attributable to study treatment * Any grade 2 or higher serious cytokine release syndrome at least possibly, probably, or definitely attributable to study treatment, particularly those affe….

Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.

The protocol identifies Lomustine as control therapy. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.

Indexed readouts in the surrounding landscape

0 recent result records were selected as contextual evidence for Glioblastoma Multiforme. These records do not establish direct evidence for NCT06177964 unless the registration number matches.

Indexed evidence status

No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.

Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.

Asset and sponsor context

Lerapolturev is indexed as Oncolytic virus with PVR biology and a global stage of Phase 2. The asset profile lists Duke University as an originator or developer.

Duke University is indexed in an unreported country with the website https://www.dukeems.org. Duke University is a private research university providing undergraduate and postgraduate education in medicine and other disciplines. The record lists 65 development-stage drug assets.

For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.

Development white space

Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
Sequencing white space. Clarify whether Lerapolturev is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.

White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.

Strategic implications and next readouts

For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.

For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.

Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.

Source trail and bottom line

Anchor trial: NCT06177964
Protocol source: https://clinicaltrials.gov/study/NCT06177964
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.

Lerapolturev in Glioblastoma Multiforme is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Proportion of patients at each dose level who experienced a dose-limiting toxicity - Stage 1 and 2029-02-01 the leading decision points.

Build and refresh clinical landscape reports with PatSnap MCP